{
  "abstract": "Background Fibroblast activating protein (FAP) expressing fibroblasts are an attractive target for cancer therapeutic depletion and while preclinical depletion shows success, previous modalities have had unsuccessful clinical impact. Here, we wanted to comprehensively understand the tumor microenvironmental changes after FAP + fibroblast depletion and unravel potential reasons for resistance and vulnerabilities that appear upon treatment with a FAP-targeted T-cell engager. To unveil the complex changes that occur in the tumor microenvironment (TME) after FAP+ fibroblast depletion, we generated comprehensive single-cell RNA-sequencing analysis of FAP+ cancer-associated fibroblasts (CAFs) depletion within the TME to understand the key populations and genetic modulations in all cell subtypes.Methods A CD3 T-cell engager directed against FAP (FAP TcE) was used to deplete FAP + fibroblasts in a preclinical murine model of pancreatic cancer. To understand complex population dynamics on FAP TcE, we performed single-cell RNA-sequencing of treated versus untreated tumors to unveil population and genetic changes.Results Administration of FAP TcE resulted in tumor growth control in vivo that was not dependent on T-cell priming and egress via draining lymph nodes. After FAP TcE, T-cell exhaustion was prevalent with an increased T-cell exhaustive state and the emergence of a T-cell progenitor exhausted state, yet the addition of anti-programmed cell death protein 1 (PD-1) failed to enhance tumor efficacy. Within fibroblast populations, FAP TcE depleted FAP + CAFs; however, depletion is compensated by an emergence of a “mixed CAF” population, potentially limiting the efficacy of FAP TcE.Conclusion This study highlights the complex and plastic fibroblast changes occurring with stroma-targeted therapies that may limit therapeutic efficacy.",
  "authors": [
    {
      "affiliations": [
        "Oncology, Boehringer Ingelheim Corp USA, Ridgefield, Connecticut, USA"
      ],
      "name": "Robert J Norgard"
    },
    {
      "affiliations": [
        "Oncology, Boehringer Ingelheim Corp USA, Ridgefield, Connecticut, USA"
      ],
      "name": "Joshua R Tagore"
    },
    {
      "affiliations": [
        "Oncology, Boehringer Ingelheim Corp USA, Ridgefield, Connecticut, USA"
      ],
      "name": "Pratha Budhani"
    },
    {
      "affiliations": [
        "Computational Innovation, Boehringer Ingelheim Corp USA, Ridgefield, Connecticut, USA"
      ],
      "name": "Sai Charan Penikalapati"
    },
    {
      "affiliations": [
        "Biotherapeutics, Boehringer Ingelheim Corp USA, Ridgefield, Connecticut, USA"
      ],
      "name": "Priyanka Gupta"
    },
    {
      "affiliations": [
        "Biotherapeutics, Boehringer Ingelheim Corp USA, Ridgefield, Connecticut, USA"
      ],
      "name": "Dongmei Liu"
    },
    {
      "affiliations": [
        "Oncology, Boehringer Ingelheim Corp USA, Ridgefield, Connecticut, USA"
      ],
      "name": "Jessica N Egan"
    },
    {
      "affiliations": [
        "Oncology, Boehringer Ingelheim Corp USA, Ridgefield, Connecticut, USA"
      ],
      "name": "Sarah F Finnegan"
    },
    {
      "affiliations": [
        "Oncology, Boehringer Ingelheim Corp USA, Ridgefield, Connecticut, USA"
      ],
      "name": "Zhuxuan Li"
    },
    {
      "affiliations": [
        "Nonclinical Safety, Boehringer Ingelheim Pharmaceutical Inc, Ridgefield, Connecticut, USA"
      ],
      "name": "Brianna Flynn"
    },
    {
      "affiliations": [
        "Oncology Research, Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria"
      ],
      "name": "Claudia Reichel-Voda"
    },
    {
      "affiliations": [
        "Oncology Research, Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria"
      ],
      "name": "Leticia Corrales"
    },
    {
      "affiliations": [
        "Oncology Research, Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria"
      ],
      "name": "Anna Bachmayr-Heyda"
    },
    {
      "affiliations": [
        "Oncology Research, Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria"
      ],
      "name": "Iñigo Tirapu"
    },
    {
      "affiliations": [
        "Oncology, Boehringer Ingelheim Corp USA, Ridgefield, Connecticut, USA"
      ],
      "name": "Abhishek S Kashyap"
    },
    {
      "affiliations": [
        "Computational Innovation, Boehringer Ingelheim Corp USA, Ridgefield, Connecticut, USA"
      ],
      "name": "Youli Xia"
    },
    {
      "affiliations": [
        "Oncology, Boehringer Ingelheim Corp USA, Ridgefield, Connecticut, USA"
      ],
      "name": "Sarah A O’Brien"
    }
  ],
  "title": "Emergence of a mixed CAF population by FAP-CD3 T-cell engager limits therapeutic efficacy",
  "uid": "19443438-6805-5470-b546-9ca87954d642"
}